Beclomethasone-dipropionate | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa03013 | RNA transport | 8.19E-04 | 7 | Q15287, Q9UBU9, P35658, P63279, P55884, O15371, P20042 | RNPS1, NXF1, NUP214, UBE2I, EIF3B, EIF3D, EIF2S2 | More | |
Beclomethasone-dipropionate | hsa03040 | Spliceosome | 3.98E-02 | 4 | Q15427, P38159, P61978, P11142 | SF3B4, RBMX, HNRPK, HSPA8 | More | |
Beclomethasone-dipropionate | hsa03060 | Protein export | 9.07E-04 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | |
Beclomethasone-dipropionate | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04012 | ErbB signaling pathway | 8.14E-03 | 4 | P21860, Q13557, O14944, P04049 | ERBB3, CAMK2D, EREG, RAF1 | More | |
Beclomethasone-dipropionate | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04020 | Calcium signaling pathway | 2.19E-05 | 10 | Q96DU7, Q08828, P45880, Q13557, P21860, P61073, P0DP24, P05141, P51828, P23634 | ITPKC, ADCY1, VDAC2, CAMK2D, ERBB3, CXCR4, CALM2, SLC25A5, ADCY7, ATP2B4 | More | |
Beclomethasone-dipropionate | hsa04022 | cGMP-PKG signaling pathway | 9.49E-04 | 9 | P04049, Q99941, P18848, P23634, Q08828, P51828, P05141, P45880, P0DP24 | RAF1, CREBL1, ATF4, ATP2B4, ADCY1, ADCY7, SLC25A5, VDAC2, CALM2 | More | |
Beclomethasone-dipropionate | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.91E-02 | 3 | Q8NHW4, P61073, Q13651 | CCL4L2, CXCR4, IL10RA | More | |
Beclomethasone-dipropionate | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04064 | NF-kappa B signaling pathway | 9.08E-04 | 8 | Q13489, Q13546, P01584, Q9UDY8, P63279, Q8NHW4, Q9UNE0, Q9NQC7 | BIRC3, RIPK1, IL1B, MALT1, UBE2I, CCL4L2, EDAR, CYLD | More | |
Beclomethasone-dipropionate | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04071 | Sphingolipid signaling pathway | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04114 | Oocyte meiosis | 4.36E-02 | 5 | Q13557, P0DP24, Q08828, P51828, P27348 | CAMK2D, CALM2, ADCY1, ADCY7, YWHAQ | More | |
Beclomethasone-dipropionate | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04141 | Protein processing in endoplasmic reticulum | 3.64E-02 | 5 | Q99941, O75460, P11142, Q9H3Z4, P07900 | CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1 | More | |
Beclomethasone-dipropionate | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04210 | Apoptosis | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04211 | Longevity regulating pathway | 3.41E-03 | 7 | Q12778, Q08828, P51828, Q99941, P18848, Q9UEF7, Q96KQ7 | FOXO1, ADCY1, ADCY7, CREBL1, ATF4, KL, EHMT2 | More | |
Beclomethasone-dipropionate | hsa04217 | Necroptosis | 6.23E-04 | 10 | P01568, P23458, Q13489, Q9NQC7, Q13546, P05141, P01584, P0C0S5, Q13557, Q9H444 | IFNA21, JAK1, BIRC3, CYLD, RIPK1, SLC25A5, IL1B, H2AFZ, CAMK2D, CHMP4B | More | |
Beclomethasone-dipropionate | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.60E-03 | 7 | Q08828, P51828, Q99941, P18848, P0DP24, Q13557, P23634 | ADCY1, ADCY7, CREBL1, ATF4, CALM2, CAMK2D, ATP2B4 | More | |
Beclomethasone-dipropionate | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | |
Beclomethasone-dipropionate | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04371 | Apelin signaling pathway | 2.65E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04380 | Osteoclast differentiation | 4.98E-02 | 4 | Q9NQC7, Q9UQC2, P23458, P01584 | CYLD, GAB2, JAK1, IL1B | More | |
Beclomethasone-dipropionate | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04540 | Gap junction | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04613 | Neutrophil extracellular trap formation | 2.65E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | |
Beclomethasone-dipropionate | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
Beclomethasone-dipropionate | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
Beclomethasone-dipropionate | hsa04623 | Cytosolic DNA-sensing pathway | 5.86E-05 | 4 | P01584, P01568, Q13546, Q8NHW4 | IL1B, IFNA21, RIPK1, CCL4L2 | More | |
Beclomethasone-dipropionate | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04650 | Natural killer cell mediated cytotoxicity | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04668 | TNF signaling pathway | 4.74E-02 | 3 | Q99941, P01584, O95429 | CREBL1, IL1B, BAG4 | More | |
Beclomethasone-dipropionate | hsa04713 | Circadian entrainment | 1.91E-02 | 4 | P0DP24, Q13557, Q08828, P51828 | CALM2, CAMK2D, ADCY1, ADCY7 | More | |
Beclomethasone-dipropionate | hsa04720 | Long-term potentiation | 5.27E-03 | 5 | Q13557, P0DP24, P18848, Q08828, P04049 | CAMK2D, CALM2, ATF4, ADCY1, RAF1 | More | |
Beclomethasone-dipropionate | hsa04722 | Neurotrophin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04725 | Cholinergic synapse | 3.77E-02 | 4 | Q08828, P51828, P18848, Q13557 | ADCY1, ADCY7, ATF4, CAMK2D | More | |
Beclomethasone-dipropionate | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04728 | Dopaminergic synapse | 2.67E-02 | 5 | Q99941, P18848, Q13557, P0DP24, O15516 | CREBL1, ATF4, CAMK2D, CALM2, CLOCK | More | |
Beclomethasone-dipropionate | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.53E-04 | 5 | P01584, Q08828, P51828, Q13557, P0DP24 | IL1B, ADCY1, ADCY7, CAMK2D, CALM2 | More | |
Beclomethasone-dipropionate | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04911 | Insulin secretion | 2.95E-05 | 5 | Q08828, P51828, Q99941, P18848, Q13557 | ADCY1, ADCY7, CREBL1, ATF4, CAMK2D | More | |
Beclomethasone-dipropionate | hsa04912 | GnRH signaling pathway | 1.74E-03 | 6 | Q08828, P51828, P18848, Q13557, P0DP24, P04049 | ADCY1, ADCY7, ATF4, CAMK2D, CALM2, RAF1 | More | |
Beclomethasone-dipropionate | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04915 | Estrogen signaling pathway | 1.26E-02 | 5 | P04049, Q99941, P51828, P07900, P11142 | RAF1, CREBL1, ADCY7, HSP90AA1, HSPA8 | More | |
Beclomethasone-dipropionate | hsa04916 | Melanogenesis | 1.80E-03 | 5 | Q13557, P0DP24, Q08828, P51828, P04049 | CAMK2D, CALM2, ADCY1, ADCY7, RAF1 | More | |
Beclomethasone-dipropionate | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04918 | Thyroid hormone synthesis | 4.47E-03 | 5 | Q08828, P51828, Q99941, P18848, P02768 | ADCY1, ADCY7, CREBL1, ATF4, ALB | More | |
Beclomethasone-dipropionate | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04925 | Aldosterone synthesis and secretion | 8.00E-06 | 7 | Q99941, P18848, Q08828, P51828, P0DP24, Q13557, P23634 | CREBL1, ATF4, ADCY1, ADCY7, CALM2, CAMK2D, ATP2B4 | More | |
Beclomethasone-dipropionate | hsa04926 | Relaxin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 4 | Q99941, P18848, Q08828, P51828 | CREBL1, ATF4, ADCY1, ADCY7 | More | |
Beclomethasone-dipropionate | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.20E-02 | 5 | Q08828, P51828, P04049, Q99941, P18848 | ADCY1, ADCY7, RAF1, CREBL1, ATF4 | More | |
Beclomethasone-dipropionate | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa04932 | Non-alcoholic fatty liver disease | 3.45E-02 | 5 | P18848, O75460, P01584, P12074, O15239 | ATF4, ERN1, IL1B, COX6A1, NDUFA1 | More | |
Beclomethasone-dipropionate | hsa04934 | Cushing syndrome | 2.69E-06 | 6 | Q99941, P18848, Q08828, P51828, O15169, Q13557 | CREBL1, ATF4, ADCY1, ADCY7, AXIN1, CAMK2D | More | |
Beclomethasone-dipropionate | hsa04935 | Growth hormone synthesis, secretion and action | 1.68E-02 | 5 | Q08828, P51828, P04049, Q99941, P18848 | ADCY1, ADCY7, RAF1, CREBL1, ATF4 | More | |
Beclomethasone-dipropionate | hsa04970 | Salivary secretion | 3.54E-02 | 3 | Q08828, P51828, P0DP24 | ADCY1, ADCY7, CALM2 | More | |
Beclomethasone-dipropionate | hsa04971 | Gastric acid secretion | 2.95E-05 | 5 | Q08828, P51828, P15311, P0DP24, Q13557 | ADCY1, ADCY7, VIL2, CALM2, CAMK2D | More | |
Beclomethasone-dipropionate | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | |
Beclomethasone-dipropionate | hsa05010 | Alzheimer disease | 2.62E-04 | 14 | Q92542, O15239, P05496, P12074, Q00535, O75460, P0DP24, P01584, P18848, O15169, P05141, P45880, P28070, P43686 | NCSTN, NDUFA1, ATP5G1, COX6A1, CDK5, ERN1, CALM2, IL1B, ATF4, AXIN1, SLC25A5, VDAC2, PSMB4, PSMC4 | More | |
Beclomethasone-dipropionate | hsa05012 | Parkinson disease | 7.90E-03 | 9 | O15239, P12074, P05141, O75460, P18848, P28070, P43686, P0DP24, Q13557 | NDUFA1, COX6A1, SLC25A5, ERN1, ATF4, PSMB4, PSMC4, CALM2, CAMK2D | More | |
Beclomethasone-dipropionate | hsa05016 | Huntington disease | 3.54E-02 | 8 | O15239, P12074, P24928, P62487, P05141, O75460, P28070, P43686 | NDUFA1, COX6A1, POLR2A, POLR2G, SLC25A5, ERN1, PSMB4, PSMC4 | More | |
Beclomethasone-dipropionate | hsa05020 | Prion disease | 1.76E-03 | 12 | P01584, P46531, P11142, O15239, P05496, P12074, P18848, P05141, P45880, P28070, P43686, Q99941 | IL1B, NOTCH1, HSPA8, NDUFA1, ATP5G1, COX6A1, ATF4, SLC25A5, VDAC2, PSMB4, PSMC4, CREBL1 | More | |
Beclomethasone-dipropionate | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.74E-03 | 13 | O15239, P12074, Q8TEV9, O75460, P18848, P05141, Q00535, O15169, P01584, P0DP24, Q13557, P28070, P43686 | NDUFA1, COX6A1, SMCR8, ERN1, ATF4, SLC25A5, CDK5, AXIN1, IL1B, CALM2, CAMK2D, PSMB4, PSMC4 | More | |
Beclomethasone-dipropionate | hsa05030 | Cocaine addiction | 3.54E-02 | 3 | Q00535, Q99941, P18848 | CDK5, CREBL1, ATF4 | More | |
Beclomethasone-dipropionate | hsa05031 | Amphetamine addiction | 7.61E-03 | 4 | P0DP24, Q13557, Q99941, P18848 | CALM2, CAMK2D, CREBL1, ATF4 | More | |
Beclomethasone-dipropionate | hsa05034 | Alcoholism | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05132 | Salmonella infection | 2.71E-03 | 5 | P04049, Q13546, Q13489, O60282, P68371 | RAF1, RIPK1, BIRC3, KIF5C, TUBB2C | More | |
Beclomethasone-dipropionate | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05160 | Hepatitis C | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05163 | Human cytomegalovirus infection | 1.52E-04 | 11 | P04049, P0DP24, Q8NHW4, Q08828, P51828, P23458, P01584, P61073, Q13651, Q99941, P18848 | RAF1, CALM2, CCL4L2, ADCY1, ADCY7, JAK1, IL1B, CXCR4, IL10RA, CREBL1, ATF4 | More | |
Beclomethasone-dipropionate | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05206 | MicroRNAs in cancer | 6.19E-04 | 7 | P15311, P21860, P61978, P46531, P63279, P22105, P04049 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB, RAF1 | More | |
Beclomethasone-dipropionate | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05212 | Pancreatic cancer | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05231 | Choline metabolism in cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Beclomethasone-dipropionate | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |